Mitochondrial fusion is a physiological process that is regulated by mitofusins on the outer 45 mitochondrial membrane. Conformational plasticity between anti-and pro-tethering 46 conformations of mitofusins permits mitochondrial tethering and subsequent fusion. Here 47 we developed a pharmacophore-based model to rationally manipulate the conformational 48 plasticity of mitofusin 2 and perfomed an in silico small-molecule screen. This enabled the 49 discovery of a direct activator of mitofusins, MASM7, capable of potently promoting 50 mitochondrial fusion. The specificity of the MASM7-mitofusin 2 interaction is highlighted 51 by structure-activity relationships of MASM7 analogues, FRET, NMR and mitochondrial 52 fusion studies using mitofusin mutants. Our study identified the first-in-class direct 53 activator of mitofusins, demonstrating a new paradigm for chemical modulation of 54 mitochondrial fusion and downstream processes. 55 56 57 Keywords: mitochondrial dynamics; mitochondrial fusion, mitofusins; pharmacophore model, in 58 silico screen, MASM7 59 60 61 62 63 64 65 66
Mitochondria are highly dynamic organelles that fuse and divide constantly. The physiological 68 processes that regulate this mitochondrial dynamism are fusion and fission, respectively (Detmer 69 et al., 2007) . A large variability in mitochondrial morphology is observed among different cell 70 types and within the same cell, as mitochondria can morph into small spheres, short rods or long 71 tubules. This dynamism allows mitochondria to exchange contents (e.g. lipid membranes, 72 proteins), promote repair, and maintain mitochondrial quality control (Shirihai et al., 2015) . interact in an anti-parallel trans manner to form homotypic (Mfn1-Mfn1 or Mfn2-Mfn2) or 82 heterotypic (Mfn1-Mfn2) complexes, subsequently mediating mitochondrial tethering (Koshiba 83 et al., 2004) . We recently proposed a model in which Mfn2 can undergo conformational 84 activation to promote mitochondrial tethering (Franco et al., 2016) . Based on this model, Mfn2 85 can adopt anti-or pro-tethering conformations ( Figure 1A ) (Franco et al., 2016) . In the anti-86 tethering conformation HR2 interacts intra-molecularly with HR1 in an anti-parallel manner 87 ( Figure 1A ). On the other hand, in the pro-tethering conformation HR1-HR2 interactions are 88 disrupted, and the HR2 domain extends into the cytosol to mediate mitochondrial tethering 89
Recently, Cao et al. (2017) demonstrated that dimerization of GTPase domains of mitofusins 91 may also control mitochondrial tethering. In contrast, Mattie et al. (2018) proposed an alternative 92 model for mitochondrial tethering, in which Mfns are activated by HR2 domain dimerization in 93 the intermembrane mitochondrial space. Further work will be needed to resolve the differences 94 in these models. 95
Irrespective of the precise tethering model, however, we and others have shown 96 disruption of the HR1-HR2 interaction is critical for mitochondrial tethering and fusion to take 97 place (Franco et al. 2016 , Huang et al., 2011 . Therefore, we sought to identify mitofusin 98 activating small molecules (MASMs) by targeting the disruption of the HR1-HR2 interaction. 99
To accomplish this, we used the HR1-HR2 interaction that is supported by the structural model 100 
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To identify small molecules that directly activate Mfn2 and promote mitochondrial fusion, we 113 subjected Mfn2 to a structure-guided pharmacophore-based approach combined with in silico 114 screening with the goal of directly promoting the pro-tethering and/or inhibiting the formation of 115 anti-tethering conformation of Mfn2. Our previous structural model of full-length Mfn2 in the 116 anti-tethering conformation (Franco et al., 2016) and the recent crystal structure of Mfn1 (Cao, et 117 al., 2017) informed us about the intra-molecular HR1-HR2 interactions,. Visual inspection of the 118 intra-molecular HR1-HR2 interactions in the human Mfn2 structural model and particularly in 119 the region that involves HR1-residues: 367-384, which our previous work using a 367-384 Gly 120 peptide suggested to regulate, provided structural insights for small molecule mimicry (Franco et 121 al., 2016) . Specifically, several hydrophobic interactions were observed between the following 122 HR1-amino acids: Val372, Met376 and HR2-amino acids: Leu724, Leu727 and Ala731 and a 123 possible hydrogen bond between the HR1-amino acid: His380 and HR2-amino acid: Asp725 124 ( Figure 1B ). All of these residues are highly conserved in Mfn2 and Mfn1 of different species 125 ( Figure S1A ). We envisioned that a small molecule capable of recapitulating the interactions of 126 the aforementioned HR1-amino acids would compete with intra-molecular HR1-HR2 127 interactions and promote Mfn2 conformational activation. Accordingly, to identify such a small 128 molecule, we generated a pharmacophore hypothesis that comprises the following features: three 129 hydrophobic interactions, an aromatic interaction and a hydrogen bond donor based on the 130 interactions of the HR1 residues: Val372, Met376 and His380 ( Figure 1C ). An in silico library of 131 13.8 x 10 6 commercially available small molecules was screened to fit the pharmacophore 132 hypothesis using PHASE ( Figure 1D ) (Dixon et al., 2006) . The top 1000 hits of the in silico 133 screen were clustered for diversity and analyzed based on the fit to residues of the HR1 domain, 134 their interactions with residues of the HR2 domain, and their molecular properties. Moreover, a 135 number of filters (e.g. elimination of hits with poor ADMET properties using Qikprop) were 136 applied to provide hits with drug-like properties (Duffy et al., 2000) . Finally, a subset of 18 137 compounds was selected for experimental validation based on their fit to the pharmacophore 138 hypothesis and molecular diversity of their scaffolds ( Figures 1D, 1E) . 139
To evaluate the capacity of the selected hits to promote a conformational activation of 140 Mfn2, a cell-based screening assay was developed based on a FRET biosensor of Mfn2, a 141 molecular tool that we had previously used to monitor the conformational changes of Mfn2 in 142 cells (Franco et al., 2016) . Based on the structural model of human Mfn2 in the anti-tethering 143 conformation and in agreement with the crystal structure of Mfn1, the N-terminus is in 144 approximate distance with the C-terminus in the HR2 domain. Therefore the N-terminus was 145 fused with mCerulean and the C-terminus in the HR2 domain was fused with mVenus ( Figure  146 2A). This FRET-based Mfn2 biosensor was transiently transfected in HEK 293T cells and co-147 localized with ATP synthase subunit beta (ATP5B), consistent with mitochondrial localization 148 ( Figure S1B ). Loss of intra-molecular HR1-HR2 interactions leads to a conformational change 149 and promotes the pro-tethering conformation of Mfn2. The increased distance between the N-150 terminus and the C-terminus, occurring in the pro-tethering conformation of Mfn2, is expected to 151 lead to a decrease in the resonance energy that is transferred ( Figure 2A ). Indeed, we previously 152 showed that the HR1-derived peptide: 367-384 Gly that promotes the pro-tethering conformation 153 of Mfn2 was able to decrease FRET, whereas the HR1-derived peptide: 398-418 Gly that 154 promotes the anti-tethering conformation of Mfn2 was able to increase FRET (Franco et al., 155 2016). Therefore, we used the HR1-derived peptide: 367-384 Gly as a positive control in our 156 assay. Next, we examined the ability of the 18 putative MASMs to promote the pro-tethering 157 conformation of Mfn2, using a decrease in FRET as a readout ( Figure 2B , Table S1 ). Strikingly, 158 indicative of promoting the pro-tethering conformation of Mfn2 ( Figure 2B ). MASM7 was 160 resynthesized to document its purity by 1 Mfn2 and our pharmacophore model hypothesis for Mfn2 activation based on conserved residues 210 that regulate HR1-HR2 interactions ( Figure S1 ). Furthermore, it is consistent with the work by 211 Transfected HEK 293T cells were washed with once PBS and fixed with 2% PFA for 13 min. 411 Subsequently, cells were blocked, then incubated for 1 h at room temperature with the primary 412 antibody for ATP5B (Abcam; ab128743). After incubation with the primary antibody, cells were 413 washed with PBS and incubated for 1 h at room temperature with the secondary antibody 414 (ThermoFisher Scientific; A11010). Images were taken with Leica SP5 inverted confocal 415 microscope or Zeiss fluorescent microscope. Data were analyzed with Image J software. 416 ....350.......360.......370.......380.......390.......400 .. ....690.......700.......710.......720.......730.......740.......750 
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